A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Ibrutinib (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms SELENE
- Sponsors Janssen Research & Development; Janssen-Cilag
- 08 Sep 2023 Status changed from active, no longer recruiting to completed.
- 29 Jun 2023 This trial has been completed in Belgium and Germany (End Date: 21 Jun 2023), according to European Clinical Trials Database record.
- 06 Apr 2023 According to an AbbVie media release, this study results will be presented at a future scientific forum.